Long-term remission of a Her2/neu positive primary breast cancer under double monoclonal antibody therapy with trastuzumab and bevacizumab

Data publikacji: 25 kwi 2014

Zakres stron: 184 - 188

Otrzymano: 27 sie 2013

Przyjęty: 18 lis 2013

DOI: https://doi.org/10.2478/raon-2013-0083

Słowa kluczowe

breast cancer, Her2/neu, trastuzumab, bevacizumab, VEGF

© by Robert Königsberg

This article is distributed under the terms of the Creative Commons Attribution Non-Commercial License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.